Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab
Julia von Tresckow
Importance of prognostic factors in the treatment of CLL and how to assess them
Can concepts from CLL be applied to other liquid and solid tumors?
What’s next for Richter’s syndrome?
Big data on efficacy and toxicity levels for ibrutinib in CLL